Gu Jianren, male, born in 1932 in Suzhou, Jiangsu Province, was an expert in molecular biology of cancer, professor, and among the first batch of academicians of the Chinese Academy of Engineering. He was the research fellow, honorary dean, and doctoral supervisor of the Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University. In 1954, he graduated from the former Shanghai First Medical University. In 1979-1981, he was the visiting scholar at Cancer Research UK Beatson Institute. In 1986-1995, he was invited for long-term cooperation and reciprocal visits with the National Institutes of Health (NIH). In 1995-1999, he was appointed as the international judge of the Awards Committee of General Motors Cancer Research Foundation. In 1987-2000, he was appointed as the director of the Expert Panel and member of the Expert Committee in the Biotechnology Field (Research Topics in Engineered Vaccines, Drugs and Gene Therapy), and responsible expert of the major projects in gene therapy of the National 863 Program. In 2001-2004, he was a member of the Second Expert Advisory Group of the National Basic Research Program (973 Program). In 2008, he was appointed as the deputy director of the Evaluation and Supervision Group of the Key Special Fund for Infectious Diseases under the Middle- and Long-Term Development Plan for the Civil Aviation Industry (2006-2010). In the past 50 years, Gu has been engaged in scientific research and teaching work in tumor pathology, tumor biochemistry, and molecular biology of tumor. In 1985, Gu established the National Key Laboratory of Oncogenes and Related Genes. From 1986 to 2002, he was the director of this Laboratory; from 2003 to 2007, he was chairman of the Academic Committee of this Laboratory. He successively undertook 15 national scientific research projects. Gu was the first to publish the activated oncogene profile in liver cancer. He won the second class prize of the State Science and Technology Award, and the first class Prize of the Science and Technology Award granted by the Ministry of Health. He discovered the high frequency of chromosome 17p13.1 (p53) deletions and proved this segment to have the highest frequency of LOH. Since 1998, Gu supervised the high-throughput functional gene screening based on cellular growth. Gu and his team discovered the full-length cDNAs of over 300 novel genes that either inhibited or suppressed cellular growth. He was granted the first class prize of the Shanghai Municipal Science and Technology Award for the above achievement. Gu is a founder of studies in cancer-related genes and gene therapy in China, proposing a new concept that tumor is a systemic disease. Gu has published over 500 papers so far, won 64 Chinese invention patents and 4 U.S. patents. He won many awards and titles, including Shanghai Advanced Medical Worker, Prize of the First Science and Technology Heroes of Shanghai, Shanghai Health System Model Workers, National May 1 Labor Medal, National Outstanding Worker, Shanghai Medical Honorary Award, Ho Leung Ho Lee Scientific and Technological Progress Award, and Guanghua Engineering Science and Technology Award.